Citations

Citations to this article as recorded by  

• Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study
  Kentaro Watanabe, Susumu Yamaguchi, Yoshinori Kosakai, Tetsuya Ioji, Hisamitsu Ishihara
  Clinical Drug Investigation.2023; 43(12): 927.     CrossRef

Citations

Citations to this article as recorded by  

• Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
  Colleen Gavigan, Thomas Donner, Christian S. Goebl
  Journal of Diabetes Research.2023; 2023: 1.     CrossRef
• Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study
  Masato Odawara, Sumiko Aoi, Tomomi Takeshima, Kosuke Iwasaki
  Diabetes Therapy.2021; 12(8): 2165.     CrossRef
• Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
  A.J. Scheen
  Diabetes & Metabolism.2020; 46(3): 186.     CrossRef
• Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
  Naoko Tajima, Jun‐ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel
  Journal of Diabetes Investigation.2020; 11(3): 640.     CrossRef
• Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
  Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks, Ross N. Butler
  Scientific Reports.2019;[Epub]     CrossRef
• Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
  Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang, Fuu-Jen Tsai
  Oncotarget.2017; 8(11): 18050.     CrossRef
• Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
  Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda
  Diabetes, Obesity and Metabolism.2017; 19(6): 874.     CrossRef
• A Practical Review of C-Peptide Testing in Diabetes
  Emma Leighton, Christopher AR Sainsbury, Gregory C. Jones
  Diabetes Therapy.2017; 8(3): 475.     CrossRef
• Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials
  S. Del Prato, S. Patel, S. Crowe, M. von Eynatten
  Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(10): 886.     CrossRef
• Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
  Dong-Sung Lee, Eun-Sol Lee, Md. Morshedul Alam, Jun-Hyeog Jang, Ho-Sub Lee, Hyuncheol Oh, Youn-Chul Kim, Zahid Manzoor, Young-Sang Koh, Dae-Gil Kang, Dae Ho Lee
  Metabolism.2016; 65(2): 89.     CrossRef
• Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis
  Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueying Gao, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
  Expert Opinion on Pharmacotherapy.2016; 17(12): 1591.     CrossRef
• Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
  Xiaoling Cai, Wenjia Yang, Xueying Gao, Lingli Zhou, Xueyao Han, Linong Ji, Francesco Giorgino
  PLOS ONE.2016; 11(12): e0166625.     CrossRef
• Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up
  Jong-Ha Baek, Bo Ra Kim, Jeong Woo Hong, Soo Kyoung Kim, Jung Hwa Jung, Jaehoon Jung, Jong Ryeal Hahm
  Kosin Medical Journal.2016; 31(2): 146.     CrossRef
• Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes
  Ken-ichi Hashimoto, Yukio Horikawa, Jun Takeda
  Diabetology International.2016; 7(2): 133.     CrossRef
• Anagliptin and sitagliptin as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, active‐controlled, phase III clinical trial with a 28‐week extension
  S.‐M. Jin, S. W. Park, K.‐H. Yoon, K. W. Min, K.‐H. Song, K. S. Park, J.‐Y. Park, I. B. Park, C. H. Chung, S. H. Baik, S. H. Choi, H. W. Lee, I.‐K. Lee, D.‐M. Kim, M.‐K. Lee
  Diabetes, Obesity and Metabolism.2015; 17(5): 511.     CrossRef
• Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
  Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
  Endocrinology and Metabolism.2015; 30(1): 84.     CrossRef
• C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes
  Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh
  Diabetes Research and Clinical Practice.2015; 108(3): 441.     CrossRef
• Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
  Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
  Diabetes & Metabolism Journal.2015; 39(6): 489.     CrossRef
• Response to the dipeptidyl peptidase‐4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin‐6 promoter region under a certain level of physical activity
  Mizue Matsui, Yoshihiko Takahashi, Noriko Takebe, Kazuma Takahashi, Kan Nagasawa, Hiroyuki Honma, Tomoyasu Oda, Mitsutaka Ono, Riyuki Nakagawa, Takayoshi Sasai, Hirobumi Togashi, Mari Hangai, Takashi Kajiwara, Haruhito Taneichi, Yasushi Ishigaki, Jo Satoh
  Journal of Diabetes Investigation.2015; 6(2): 173.     CrossRef
• Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
  Ji Hyun Kim
  Diabetes & Metabolism Journal.2015; 39(4): 304.     CrossRef
• Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
  Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho
  Diabetes & Metabolism Journal.2015; 39(4): 335.     CrossRef
• GLP-1: The Oracle for Gastric Bypass?
  Gema Frühbeck, Ruben Nogueiras
  Diabetes.2014; 63(2): 399.     CrossRef
• Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes
  Takumi Hirata, Kouichi Inukai, Jiro Morimoto, Shigehiro Katayama, Hitoshi Ishida
  Primary Care Diabetes.2014; 8(3): 265.     CrossRef
• Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes
  Yukihiro Bando, Masayuki Yamada, Keiko Aoki, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji, Daisyu Toya, Nobuyoshi Tanaka
  Diabetology International.2014; 5(4): 229.     CrossRef
• The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
  Eun Yeong Choe, Yongin Cho, Younjeong Choi, Yujung Yun, Hye Jin Wang, Obin Kwon, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
  Diabetes & Metabolism Journal.2014; 38(3): 211.     CrossRef
• Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
  Kazuki Murai, Tomoyuki Katsuno, Jun-ichiro Miyagawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Yoshiki Kusunoki, Masayuki Miuchi, Mitsuyoshi Namba
  Drugs in R&D.2014; 14(4): 301.     CrossRef
• Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI
  Swneke D. Bailey, Changchun Xie, Guillaume Paré, Alexandre Montpetit, Viswanathan Mohan, Salim Yusuf, Hertzel Gerstein, James C. Engert, Sonia S. Anand
  Diabetologia.2014; 57(4): 738.     CrossRef
• Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride
  Rieko Umayahara, Takako Yonemoto, Chika Kyou, Kae Morishita, Tatsuo Ogawa, Yoshitaka Taguchi, Tatsuhide Inoue
  Endocrine Journal.2014; 61(12): 1163.     CrossRef
• The clinical utility of C‐peptide measurement in the care of patients with diabetes
  A. G. Jones, A. T. Hattersley
  Diabetic Medicine.2013; 30(7): 803.     CrossRef
• Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study
  Naotsuka Okayama, Kenro Imaeda, Takashi Kato, Soji Iwase, Hideomi Ohguchi, Takashi Joh, Yoshinari Hayashi, Masaya Akao, Kohei Ogawa, Mayo Hachiya, Rei Hattori, Ryosuke Kimura, Sachie Yasui, Misao Ando, Yasunari Jinno, Nobuo Takahashi, Manabu Shimizu, Nobo
  Diabetology International.2013; 4(3): 179.     CrossRef
• Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
  Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
  Journal of Korean Medical Science.2013; 28(6): 881.     CrossRef
• Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes
  Yukihiro Bando, Kazuhide Ishikura, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka
  Diabetology International.2013; 4(4): 251.     CrossRef
• The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
  Jun Sung Moon, Kyu Chang Won
  Diabetes & Metabolism Journal.2013; 37(1): 36.     CrossRef
• Factors Influencing Glycemic Control Response of Sitagliptin
  Gun Woo Kim, Jae Hyun Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Eun Ho Ha, Choon Hee Chung
  The Journal of Korean Diabetes.2013; 14(4): 206.     CrossRef
• Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
  S-I. Harashima, M. Ogura, D. Tanaka, T. Fukushima, Y. Wang, T. Koizumi, M. Aono, Y. Murata, M. Seike, N. Inagaki
  International Journal of Clinical Practice.2012; 66(5): 465.     CrossRef
• Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
  Soo Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang
  Clinical Endocrinology.2012; 77(2): 215.     CrossRef
• Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
  Yuji Tajiri, Munehisa Tsuruta, Tsuyoshi Ohki, Tomoko Kato, Yuko Sasaki, Kayo Tanaka, Shusuke Kono, Masayuki Tojikubo, Kentaro Yamada
  Endocrine Journal.2012; 59(3): 197.     CrossRef
• Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study
  E. S. Hong, A. R. Khang, J. W. Yoon, S. M. Kang, S. H. Choi, K. S. Park, H. C. Jang, H. Shin, G. A. Walford, S. Lim
  Diabetes, Obesity and Metabolism.2012; 14(9): 795.     CrossRef
• Letter: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
  Jee-Young Oh
  Diabetes & Metabolism Journal.2011; 35(3): 298.     CrossRef
• Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
  Yun-Mi Jang, Dong-Lim Kim
  Diabetes & Metabolism Journal.2011; 35(2): 117.     CrossRef